ESK-001 Phase 2 Psoriasis Data at AAD 2024

Alumis Inc., a biopharmaceutical firm specializing in the development of targeted oral treatments for immune-mediated diseases, has scheduled two clinical data presentations at the forthcoming American Academy of Dermatology Annual Meeting. The event is set to take place from March 8 to 12, 2024, in San Diego, California. The company's lead drug candidate, ESK-001, is a highly selective oral TYK2 inhibitor that is being assessed for its efficacy in treating various conditions, including moderate to severe plaque psoriasis, systemic lupus erythematosus (SLE), and non-infectious uveitis.

The first presentation will focus on the efficacy and safety of ESK-001 in a Phase 2 clinical trial known as STRIDE, which is aimed at adults suffering from moderate-to-severe plaque psoriasis. This oral presentation is scheduled for March 9, at 10:20 a.m. PT, in Room 20B, and will be part of the Late-Breaking Research Session 1.

Additionally, an e-poster presentation will delve into the pharmacokinetic and pharmacodynamic properties of ESK-001 as observed in Phase 1 trials involving healthy volunteers. This poster, identified by the number 53968, will provide insights into the drug's behavior within the body and its effects on the biological system.

Following the Phase 2 data unveiling, Alumis plans to host a virtual investor event to discuss the clinical findings in more detail. Interested parties can register for the webcast through the Events section of Alumis' official website.

Alumis is recognized for its precision data analytics and a multi-platform strategy, which are instrumental in advancing its pipeline of oral therapies designed to rectify immune dysfunction. The company's mission is to enhance patient outcomes and significantly improve the quality of life for those affected by immune-mediated diseases. Alumis is backed by a team of seasoned professionals with a strong background in drug development and immunology, and it is supported by Foresite Labs, an incubator with a track record of fostering innovation in the pharmaceutical sector.